Volume 26, Issue 7 (Oct 2018)
JSSU 2018, 26(7): 553-564 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mirzaei R, Nemati mansour F, mahdavi M. Formulation of hepatitis B vaccine in MF59 adjuvant and comparison of its immunization with Iran's commercial hepatitis B vaccine. JSSU 2018; 26 (7) :553-564
URL: http://jssu.ssu.ac.ir/article-1-4434-en.html
URL: http://jssu.ssu.ac.ir/article-1-4434-en.html
Abstract: (4225 Views)
Introduction: Hepatitis is a systemic diseasethat causes liver inflammation. The prevention of this infection is a vaccination. The commonly used vaccine to fight this disease is to use the vaccine formulated with Alum. This vaccine cannot provide immune response and complete productivity in some people. In this study, cellular and humoral immune responses of hepatitis B vaccine were compared with hepatitis B vaccine formulated in MF59 adjuvant.
Methods: In this experimental study, Balb/c mice received different formulations of the vaccine subcutaneously three times with a two-week interval. Then, the mice were bled and the levels of anti-HBs Ag were determined by the ELISA method. IFN-γ, IL-4, IL-2 and IFN-γ / IL-4 cytokines were examined by the ELISA method from the soup of spleen cells culture. The data were analyzed using the GraphPad prism software ANOVA.
Results: IL-4 levels were significantly higher in alum vaccine than the vaccine formulated in MF59, also the IFN-γ cytokine level showed no significant difference between two main groups. TNF-α cytokine shows that alum vaccine is more secreted due to the high inflammation compared with the vaccine with MF59. Total antibody in the third injection, in some dilutions of the commercial vaccine was more than vaccine with MF59.
Conclusion: Significant decrease in IL-4 and antibodies indicates that the tendency of vaccine formulated in MF59 to induce cellular immune responses is higher than humoral immune responses. In addition, the safety and lack of side effects of the MF59 adjuvant can also be considered as another advantage.
Methods: In this experimental study, Balb/c mice received different formulations of the vaccine subcutaneously three times with a two-week interval. Then, the mice were bled and the levels of anti-HBs Ag were determined by the ELISA method. IFN-γ, IL-4, IL-2 and IFN-γ / IL-4 cytokines were examined by the ELISA method from the soup of spleen cells culture. The data were analyzed using the GraphPad prism software ANOVA.
Results: IL-4 levels were significantly higher in alum vaccine than the vaccine formulated in MF59, also the IFN-γ cytokine level showed no significant difference between two main groups. TNF-α cytokine shows that alum vaccine is more secreted due to the high inflammation compared with the vaccine with MF59. Total antibody in the third injection, in some dilutions of the commercial vaccine was more than vaccine with MF59.
Conclusion: Significant decrease in IL-4 and antibodies indicates that the tendency of vaccine formulated in MF59 to induce cellular immune responses is higher than humoral immune responses. In addition, the safety and lack of side effects of the MF59 adjuvant can also be considered as another advantage.
Type of Study: Original article |
Subject:
Immunology
Received: 2017/12/31 | Accepted: 2018/02/10 | Published: 2018/12/23
Received: 2017/12/31 | Accepted: 2018/02/10 | Published: 2018/12/23
References
1. 1- Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 201; 62(5): 760-5.
2. 2- Merat S, Malekzadeh R, Rezvan H, Khatibian M. Hepatitis B in Iran. Arch Iran Med. 2000 Jan 1; 3(4): 192-201.
3. 3- Hervás-Stubbs S, Berasain C, Golvano J, Lasarte JJ, Prieto I, Sarobe P, et al. Overcoming class II-linked non-responsiveness to hepatitis B vaccine. Vaccine 1994;12(10): 867-71.
4. 4- Alper C. Genetic Prediction Of Non-Response To Hepatitis B Vaccine. The Pediatric Infectious Disease J 1990; 9(8): 603.
5. 5- Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. Aids 2005; 19(14): 1473-79.
6. 6- Tsai TF. MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines. Yakugaku Zasshi 2011; 131(12): 1733-41.
7. 7- Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3(85): 85ra48.
8. 8- Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 1996; 14(6): 478-84.
9. 9- Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, Ott G, et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cellular immunology 1998; 186(1): 18-27.
10. 10- Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59™ adjuvant. Vaccine 2008; 26(26): 3209-22.
11. 11- Wang S, Liu X, Caulfield MJ. Adjuvant synergy in the response to hepatitis B vaccines. Vaccine 2003; 21(27-30): 4297-306.
12. 12- Zhang X, He P, Hu Z, Wang X, Liang Z. Enhanced specific immune responses by CpG DNA in mice immunized with recombinant hepatitis B surface antigen and HB vaccine. Virol J 2011; 8(1): 78.
13. 13- Sönmez E, Sönmez AS, Bayindir Y, Coskun D, Aritürk S. Antihepatitis B response to hepatitis B vaccine administered simultaneously with tetanus toxoid in nonresponder individuals. Vaccine 2002; 21(3-4): 243-6.
14. 14- Glenny A, Buttle G, Stevens MF. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea‐pigs: Toxoid precipitated with alum. J Pathology 1931; 34(2): 267-75.
15. 15- Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2(15): 15ra5-ra5.
16. 16- Ou H, Yao H, Yao W, Wu N, Wu X, Han C, et al. Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice. Vaccine 2016; 34(20): 2362-70.
17. 17- Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996; 174(6): 1168-75.
18. 18- Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5(7) 505-17.
19. 19- Mosca, Flaviana. Activation of innate immunity by human vaccine adjuvants at injection site. Diss alma 2009.
20. 20- Nouri A, Laraba-Djebari F. Enhancement of long-lasting immunoprotective effect against Androctonus australis hector envenomation using safe antigens: Comparative role of MF59 and Alum adjuvants. Vaccine 2015; 33(43): 5756-63.
21. 21- Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008; 26(4): 552-61.
22. 22- Ko EJ, Lee YT, Kim KH, Jung YJ, Lee Y, Denning TL, et al. Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells. J virology 2016; 90(15): 6976-88.
23. O’Hagan D, Ott G, De Gregorio E, Seubert A. The mechanism of action of MF59–an innately attractive adjuvant formulation. Vaccine 2012; 30(29):4341-8
24.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
